By Fineline Cube Nanjing Pharmaceutical Co., Ltd. (SHA: 600713) announced that its holding subsidiary, Nanjing Pharmaceutical Group Qianglian No. 1 Equity Investment Fund Co., Ltd. (Qianglian No. 1 Fund), has acquired a 44.95% stake in Beijing Datsing Bio-Tech Co., Ltd. (Datsing Bio-Tech) and a 50.98% stake in Beijing Kejian Technology Co., Ltd. (Kejian Technology) for a total consideration of approximately RMB 750 million (≈ USD 104 million).
Transaction Details & Ownership Structure
| Item | Detail |
|---|---|
| Acquirer | Nanjing Pharmaceutical Group Qianglian No. 1 Equity Investment Fund |
| Parent Company | Nanjing Pharmaceutical Co., Ltd. (SHA: 600713) |
| Target Companies | Beijing Datsing Bio-Tech Co., Ltd. Beijing Kejian Technology Co., Ltd. |
| Stake Acquired | 44.95% in Datsing Bio-Tech 50.98% in Kejian Technology |
| Total Consideration | RMB 750 million (~USD 104 million) |
| Transaction Type | Strategic equity investment |
| Announcement Date | 8 July 2026 |
Target Company Profiles & Strategic Rationale
- Beijing Datsing Bio-Tech Co., Ltd.: A biotechnology company focused on innovative drug development and biopharmaceutical manufacturing, with expertise in recombinant protein therapeutics and cell-based therapies. The 44.95% stake positions Nanjing Pharmaceutical as the largest single shareholder.
- Beijing Kejian Technology Co., Ltd.: A technology-driven enterprise specializing in pharmaceutical equipment, automation systems, and digital solutions for pharmaceutical manufacturing, supporting industry modernization and compliance with international GMP standards.
The dual acquisition reflects Nanjing Pharmaceutical’s vertical integration strategy, combining upstream biotechnology capabilities with downstream manufacturing technology to strengthen its position across the pharmaceutical value chain.
Financial Implications & Investment Strategy
Capital Allocation: The RMB 750 million investment represents a significant strategic allocation by Nanjing Pharmaceutical, demonstrating confidence in China’s biopharmaceutical innovation ecosystem and manufacturing modernization trends.
Control Position: With 50.98% ownership of Kejian Technology, Nanjing Pharmaceutical gains majority control, enabling direct influence over strategic direction and operational decisions. The 44.95% stake in Datsing Bio-Tech provides substantial influence while potentially preserving the target’s entrepreneurial culture.
Synergy Opportunities: The transaction creates multiple synergy pathways:
- R&D Collaboration: Access to Datsing’s innovative pipeline and development expertise
- Manufacturing Integration: Implementation of Kejian’s advanced equipment and automation solutions across Nanjing Pharmaceutical’s production facilities
- Technology Transfer: Cross-pollination of digital and biomanufacturing capabilities between portfolio companies
Market Context & Industry Trends
- Biopharma Consolidation: The deal occurs amid accelerating consolidation in China’s pharmaceutical sector, as established players seek to acquire innovative capabilities and technological expertise.
- Government Support: Both acquisitions align with China’s national strategies to enhance domestic biopharmaceutical innovation and reduce reliance on imported technologies and therapeutics.
- Investment Vehicle Strategy: The use of a dedicated equity investment fund (Qianglian No. 1 Fund) provides Nanjing Pharmaceutical with flexible capital deployment mechanisms for future strategic acquisitions.
Forward‑Looking Statements
This brief contains information regarding strategic investments and business combinations. Actual integration outcomes may differ due to regulatory approvals, market conditions, operational challenges, and competitive dynamics.-Fineline Info & Tech